Highest-materiality recent filing
Appoints Eva Boratto as EVP and CFO effective June 29, 2026; succeeds James Cleary retiring.
Cencora Q2 revenue $78.4B (+3.8%); adj. EPS $4.75 (+7.5%); FY2026 guidance raised
GAAP diluted EPS $8.40 vs $3.68; adjusted diluted EPS $4.75 vs $4.42 (+7.5%).
Cencora to buy EyeSouth retina business for $1.1B; expects slight EPS accretion
Acquires EyeSouth Partners' retina business for $1.1B; physicians to join Retina Consultants of America.
Cencora CFO James F. Cleary to retire June 30, 2026; FY2026 guidance reaffirmed
James F. Cleary, EVP and CFO, will retire effective June 30, 2026; advisory role through end of 2026.
MWI valued at $3.5B enterprise value; Cencora gets $1.25B cash, $800M preferred units, $1.45B common units.
Cencora closes $3.0B senior notes offering, proceeds to repay OneOncology acquisition debt
$500M each of 3.950% notes due 2029, 4.250% notes due 2030, 4.600% notes due 2033, 5.650% notes due 2056; $1.0B of 4.900% notes due 2036.
$3.0B aggregate of senior notes in five tranches: 2029 (3.950%), 2030 (4.250%), 2033 (4.600%), 2036 (4.900%), 2056 (5.650%).
New segments: U.S. Healthcare Solutions, International Healthcare Solutions, and Other.
Cencora Q1 EPS $2.87 GAAP, $4.08 adjusted; acquires OneOncology for $4.6B
Revenue $85.9B, +5.5% YoY; GAAP diluted EPS $2.87 vs $2.50 prior year; adjusted diluted EPS $4.08 vs $3.73, +9.4%.
Cencora secures $5.5B in financing for OneOncology acquisition; $4.5B bridge replaced
Revolving credit facility increased by $1.0B to $5.5B via amendment on Jan 12, 2026.
Cencora acquires OneOncology majority stake for $3.6B, retires $1.3B debt; total cash ~$5.0B
Enterprise value $7.4B; Cencora paying $3.6B for majority equity and retiring $1.3B OneOncology debt.
Cencora Q4 adj EPS $3.84 (+15%); revenue $83.7B; raises dividend 9%; new segment structure
Q4 GAAP diluted EPS $(1.75) (prior yr $0.02); adjusted EPS $3.84 (+15% YoY); revenue $83.7B (+5.9%).
Cencora reaches $111.3M settlement of derivative suit over opioid oversight
Insurance carriers to pay Cencora $111.3M (less attorney fees) to settle derivative claims over controlled substance diversion controls.
Cencora Q3 FY2025 revenue $80.7B (+8.7% YoY); adj. EPS $4.00, guidance raised to $15.85-$16.00
Revenue $80.7B (+8.7% YoY); GAAP diluted EPS $3.52 vs $2.42; adj. EPS $4.00, up 19.8%.
Cencora upsizes revolver to $4.5B, extends maturity to 2030; terminates $1.0B 364-day facility
Amended revolving credit facility increased to $4.5 billion aggregate commitments; maturity extended to June 4, 2030.
Cencora issues €1B in senior notes across 2028 and 2032 maturities
Issued €500M of 2.875% Senior Notes due May 22, 2028.
Cencora Q2 FY2025 revenue $75.5B (+10.3% YoY); adj. EPS $4.42 (+16.3%); raises FY guidance
Revenue $75.5B, +10.3% YoY; GAAP diluted EPS $3.68 vs $2.09 prior year.
Cencora Q1 revenue $81.5B +12.8% YoY; adjusted EPS $3.73, raises FY2025 guidance
Revenue $81.5B (+12.8% YoY); GAAP diluted EPS $2.50 (down from $2.98); adjusted diluted EPS $3.73 (+13.7%).
Cencora acquires ~85% interest in Retina Consultants of America for $4.4B cash outlay, with post-closing adjustment.
Cencora closes $1.8B senior notes offering to fund Retina Consultants of America acquisition
Issued $500M 4.625% notes due 2027, $600M 4.850% notes due 2029, $700M 5.150% notes due 2035.
Cencora prices $1.8B debt offering in three tranches to fund Retina Consultants acquisition
$500M 4.625% senior notes due 2027, $600M 4.850% notes due 2029, $700M 5.150% notes due 2035 priced.
Cencora enters $1.5B term loan and $1.0B revolver to fund Retina Consultants of America acquisition
$1.5B senior unsecured term loan entered Nov 26, 2024; matures 3 years from draw.
Cencora to acquire Retina Consultants of America for $4.6B, ~85% ownership, accretive $0.35
Enterprise value of $4.6B cash; expected cash outlay ~$4.3B after physician/management rollover and fees.
Cencora Q4 adjusted EPS $3.34, revenue $79.1B (+14.7% YoY); dividend up 8%
Q4 GAAP EPS $0.02 vs $1.72 prior year; adjusted EPS $3.34 (+16.8% YoY) on revenue $79.1B (+14.7% YoY).
Adjusted diluted EPS for FY2024 raised to $13.60-$13.70 from prior $13.55-$13.65.
Cencora entered into indemnification agreements with board members and executive officers, effective August 13, 2024.
Cencora confirms PII/PHI exfiltration in Feb 2024 cyber incident; notifications ongoing
Exfiltrated data includes personally identifiable and protected health information, most from patient support subsidiary.
Revenue $74.2B (+10.9% YoY); GAAP diluted EPS $2.42 vs $2.35; adjusted diluted EPS $3.34 vs $2.92.
Repurchased 1,859,390 shares at $215.1244/share from Walgreens Boots Alliance Holdings for ~$400M.
Cencora Q2 revenue $68.4B, up 7.8% YoY; adj diluted EPS $3.80, up 8.6%; FY2024 guidance raised
Revenue $68.4B for quarter ended March 31, 2024, +7.8% YoY.
Cencora CEO Collis to retire Oct 1, COO Mauch to become President and CEO
Steven H. Collis will retire as CEO on Oct 1, 2024, becoming Executive Chairman for one year.
Ms. Battaglia will be succeeded by Samantha L. Hammock, who will join the Company as Executive Vice President and Chief Human Resources Officer effective July 13, 2026.
On June 15, 2026, Cencora, Inc. (the “Company”) announced that Silvana Battaglia will retire as Executive Vice President and Chief Human Resources Officer of the Company effective July 12, 2026.
On May 27, 2026, Cencora, Inc. (the “Company”) announced that Eva C. Boratto has been appointed Executive Vice President and Chief Financial Officer of the Company (the “Appointment”), effective June 29, 2026 (the “Effective Date”).
Ms. Boratto succeeds James F. Cleary, who will be retiring from his role as Executive Vice President and Chief Financial Officer as previously disclosed.
the Board of Directors (the “Board”) of Cencora, Inc. (the “Company”) appointed Lori J. Ryerkerk to serve on the Board (the “Appointment”), with such Appointment to be effective as of June 1, 2025
Ornella Barra informed the Company of her intent to resign from the Board effective immediately
On January 22, 2025, two members of the Board of Directors (the “Board”) of Cencora, Inc. (the “Company”), Richard W. Gochnauer and Kathleen W. Hyle, each informed the Company of their intent to retire as directors at the upcoming Annual Meeting of Stockholders to be held on March 6, 2025 (the “Annual Meeting”).
On January 22, 2025, two members of the Board of Directors (the “Board”) of Cencora, Inc. (the “Company”), Richard W. Gochnauer and Kathleen W. Hyle, each informed the Company of their intent to retire as directors at the upcoming Annual Meeting of Stockholders to be held on March 6, 2025 (the “Annual Meeting”).
On August 13, 2024, the Board of Directors (the "Board") of Cencora, Inc. (the "Company") appointed Frank Clyburn to serve on the Board (the "Appointment"), with such Appointment to be effective as of October 1, 2024 (the "Effective Date").
On April 30, 2024, Gina K. Clark, Executive Vice President and Chief Communications & Administrative Officer of Cencora, Inc. (the “Company”), informed the Company that she intends to retire from her position, effective September 30, 2024.
On March 12, 2024, the Company and Mr. Mauch entered into an amended and restated employment agreement (the “Mauch Employment Agreement”), effective as of the Effective Date.
For a period of one year from the Effective Date, Mr. Collis will serve as Executive Chairman of the Board (the “Executive Chairman Period”).
Max materiality 0.90 · Median 0.60 · Most common event debt